CompletedPhase 2ACTRN12610000780055

Pioglitazone in the treatment of acromegaly

The effects on insulin-like growth factor 1 (IGF-1) and growth hormone levels using Pioglitazone in the treatment of active acromegaly

Sponsor

Auckland district health board

Enrollment

20 participants

Start Date

Jun 1, 2009

Study Type

Interventional

Conditions

Acromegaly

Summary

To study the effects of pioglitazone (3 months at maximum dose of 45mg) on disease activity of acromegaly, as measured by IGF-1 level.

Eligibility

Sex: Both males and females

Plain Language Summary

Simplified for easier understanding

This study tests whether pioglitazone, a diabetes medication, can help lower growth hormone levels in people with acromegaly, a condition where the body makes too much growth hormone. People with active acromegaly who are post-menopausal or have had specific hormonal treatments may be eligible.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Pioglitazone - 1month run in period of 15mg (2 weeks) and 30mg (2 weeks)orally daily, then target dose of 45mg orally daily for further 3 months

Locations(1)

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000780055

Related Trials

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT0693062571 locations

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

NCT0703742045 locations